에 대한 최신 뉴스 Molina Healthcare (NYSE:MOH) 주식

Molina Healthcare

Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.

News

Movers

시그나 그룹(NYSE:CI), 몰리나 헬스케어(NYSE:MOH), 유나이티드헬스 그룹(NYSE:UNH) 같은 주요 의료 서비스 회사들의 주가는 도널드 트럼프 대통령이 헬스케어 산업의 가격 투명성 규제를 강화하기 위한 행정명령에 서명한 이후 수요일(26일) 하락했다.

헬스케어 주식, 트럼프의 가격 투명성 관련 행정명령 서명 이후 하락세

Analyst Color

Earnings Beats

Large Cap

Guidance

Health Care

Analyst Ratings

General

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

미국의 의료 보험 회사 휴매나(NYSE:HUM)의 주식은 수요일 소폭 상승 마감했다. 화요일 이 회사는 4분기 조정 주당순이익이 2.16달러 손실이라고 발표했다. 이는 전년 대비 11센트 감소한 수치로, 컨센서스와 일치하며 별 등급제에 대한 추가 투자를 포함한 것이다.

휴매나의 2025 전망, 산업 압박에도 불구하고 조심스러운 낙관론을 보여

Equities

Global

Markets

ACIC

BABA

BIDU

FOUR

2008년 금융 위기를 예측한 것으로 유명한 헤지펀드 매니저인 마이클 버리(Michael Burry)는 2008년 금융 위기를 예측한 것으로 유명한 헤지펀드 매니저로, 최근 중국 기술 기업에 대한 노출을 크게 늘렸으며 동시에 잠재적 하방 위험에 대한 보호 조치를 시행했다고 규제 공시에서 밝혔다.

&#39;빅 쇼트&#39; 투자자 마이클 버리, 중국 기술주에 베팅 확대하면서 보호 헤지 추가

Molina Healthcare Inc

MOTOR OIL HELLAS CORINTH by Motor Oil (Hellas) Corinth Refineries S.A.

Motor Oil (Hellas) Corinth Refineries SA

MOTOR OIL HELLAS UNSP/ADR by Motor Oil (Hellas) Corinth Refineries S.A.

Collaborative Investment Series Trust Mohr Growth ETF

Mohawk Industries Inc

Steven J Orlando, Director at Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), executed a substantial insider sell on March 5, according to an SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001179929/000117992925000031//Archives/edgar/data/1179929/000117992925000031/0001179929-25-000031-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday showed that Orlando sold 1,000 shares of Molina Healthcare. The total transaction amounted to $301,330. 
The latest update on Wednesday morning shows Molina Healthcare shares up by 0.81%, trading at $308.96.
<h3>Discovering Molina Healthcare: A Closer Look</h3>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Key Indicators: Molina Healthcare's Financial Health</h3>
Revenue Growth: Molina Healthcare's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 16.04%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 10.6%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Molina Healthcare's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 4.482143.
</li>
</ul>
Debt Management: Molina Healthcare's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.69, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 15.01 is lower than the industry average, implying a discounted valuation for Molina Healthcare's stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 0.44, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a lower-than-industry-average EV/EBITDA ratio of 5.89, Molina Healthcare presents a potential value opportunity, as investors are paying less for each unit of EBITDA.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Understanding the Significance of Insider Transactions</h3>
Investors should view insider transactions as part of a multifaceted analysis and not rely solely on them for decision-making.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>A Deep Dive into Insider Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001179929">Check Out The Full List Of Molina Healthcare's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

Insider Decision: Steven J Orlando Offloads $301K Worth Of Molina Healthcare Stock

Mark Lowell Keim, Chief Financial Officer at Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), disclosed an insider purchase on March 5, based on a new SEC filing.
What Happened: In a significant move reported in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001179929/000117992925000032//Archives/edgar/data/1179929/000117992925000032/0001179929-25-000032-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday, Keim purchased 19,425 shares of Molina Healthcare, demonstrating confidence in the company's growth potential. The total value of the transaction stands at $5,736,455.
At Wednesday morning, Molina Healthcare shares are up by 0.81%, trading at $308.96.
<h3>Get to Know Molina Healthcare Better</h3>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Unraveling the Financial Story of Molina Healthcare</h3>
Revenue Growth: Molina Healthcare's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 16.04%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 10.6%, indicating concerns regarding cost management and overall profitability relative to its industry counterparts.
</li>
<li>
Earnings per Share (EPS): Molina Healthcare's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 4.482143.
</li>
</ul>
Debt Management: Molina Healthcare's debt-to-equity ratio stands notably higher than the industry average, reaching 0.69. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Exploring Valuation Metrics Landscape:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 15.01, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 0.44 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio lower than industry averages at 5.89, Molina Healthcare could be considered undervalued.
</li>
</ul>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Pay Attention to Insider Transactions</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Important Transaction Codes</h3>
Surveying the realm of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001179929">Check Out The Full List Of Molina Healthcare's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Move: Mark Lowell Keim Invests $5.74M In Molina Healthcare Stock

In a recent SEC filing, it was revealed that Joseph M Zubretsky, President &amp; CEO at Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), made a noteworthy insider purchase on March 5,.
What Happened: Zubretsky's recent purchase of 65,487 shares of Molina Healthcare, disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001179929/000117992925000033//Archives/edgar/data/1179929/000117992925000033/0001179929-25-000033-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday, reflects confidence in the company's potential. The total transaction value is $19,427,062.
During Wednesday's morning session, Molina Healthcare shares up by 0.81%, currently priced at $308.96.
<h3>About Molina Healthcare</h3>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Understanding the Numbers: Molina Healthcare's Finances</h3>
Revenue Growth: Molina Healthcare's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 16.04%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Navigating Financial Profits:
<ul>
<li>
Gross Margin: The company faces challenges with a low gross margin of 10.6%, suggesting potential difficulties in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Molina Healthcare's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 4.482143.
</li>
</ul>
Debt Management: Molina Healthcare's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.69, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 15.01 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 0.44 is lower than the industry average, implying a discounted valuation for Molina Healthcare's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio of 5.89 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
</li>
</ul>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Cracking Transaction Codes</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001179929">Check Out The Full List Of Molina Healthcare's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

President & CEO At Molina Healthcare Buys $19.43M of Stock

In a recent SEC filing, it was revealed that James Woys, Chief Operating Officer at Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), made a noteworthy insider purchase on March 5,.
What Happened: Woys demonstrated confidence in Molina Healthcare by purchasing 15,564 shares, as reported in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001179929/000117992925000034//Archives/edgar/data/1179929/000117992925000034/0001179929-25-000034-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday. The total value of the transaction is $4,605,407.
The latest update on Wednesday morning shows Molina Healthcare shares up by 0.81%, trading at $308.96.
<h3>All You Need to Know About Molina Healthcare</h3>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>A Deep Dive into Molina Healthcare's Financials</h3>
Revenue Growth: Molina Healthcare's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 16.04%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 10.6%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Molina Healthcare's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 4.482143.
</li>
</ul>
Debt Management: Molina Healthcare's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.69, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Valuation Analysis:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 15.01, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 0.44, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a below-average EV/EBITDA ratio of 5.89, Molina Healthcare presents an opportunity for value investors. This lower valuation may attract investors seeking undervalued opportunities.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Navigating the World of Insider Transaction Codes</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001179929">Check Out The Full List Of Molina Healthcare's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

James Woys Takes a Bullish Stance: Acquires $4.61M In Molina Healthcare Stock

Disclosed in the latest SEC filing, a significant insider purchase on March 5, involves Maurice Hebert, Chief Accounting Officer at Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>).
What Happened: In a recent Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001179929/000117992925000035//Archives/edgar/data/1179929/000117992925000035/0001179929-25-000035-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday, Hebert increased their investment in Molina Healthcare by purchasing 2,694 shares through open-market transactions, signaling confidence in the company's potential. The total transaction value is $799,491.
At Wednesday morning, Molina Healthcare shares are up by 0.81%, trading at $308.96.
<h3>Unveiling the Story Behind Molina Healthcare</h3>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Breaking Down Molina Healthcare's Financial Performance</h3>
Revenue Growth: Molina Healthcare displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 16.04%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: With a low gross margin of 10.6%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Molina Healthcare's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 4.482143.
</li>
</ul>
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.69, caution is advised due to increased financial risk.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 15.01 is lower than the industry average, implying a discounted valuation for Molina Healthcare's stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 0.44, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio lower than industry benchmarks at 5.89, Molina Healthcare presents an attractive value opportunity.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
Considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Important Transaction Codes</h3>
Surveying the realm of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001179929">Check Out The Full List Of Molina Healthcare's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Confidence On Display: Maurice Hebert Acquires $799K In Molina Healthcare Stock

On March 5, a substantial insider purchase was made by Debra Bacon, EVP at Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), as per the latest SEC filing.
What Happened: Bacon's recent purchase of 9,659 shares of Molina Healthcare, disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001179929/000117992925000036//Archives/edgar/data/1179929/000117992925000036/0001179929-25-000036-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday, reflects confidence in the company's potential. The total transaction value is $2,868,816.
As of Wednesday morning, Molina Healthcare shares are up by 1.15%, currently priced at $310.0.
<h3>About Molina Healthcare</h3>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Key Indicators: Molina Healthcare's Financial Health</h3>
Positive Revenue Trend: Examining Molina Healthcare's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 16.04% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Interpreting Earnings Metrics:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 10.6%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Molina Healthcare's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 4.482143.
</li>
</ul>
Debt Management: Molina Healthcare's debt-to-equity ratio surpasses industry norms, standing at 0.69. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Exploring Valuation Metrics Landscape:
<ul>
<li>
Price to Earnings (P/E) Ratio: Molina Healthcare's P/E ratio of 15.01 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 0.44 is lower than the industry average, implying a discounted valuation for Molina Healthcare's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Molina Healthcare's EV/EBITDA ratio at 5.89 suggests potential undervaluation, falling below industry averages.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Breaking Down the Significance of Transaction Codes</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001179929">Check Out The Full List Of Molina Healthcare's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EVP Of Molina Healthcare Purchased $2.87M In Stock

In a recent SEC filing, it was revealed that Jeff D Barlow, Chief Legal Officer at Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), made a noteworthy insider purchase on March 5,.
What Happened: Barlow's recent purchase of 12,741 shares of Molina Healthcare, disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001179929/000117992925000037//Archives/edgar/data/1179929/000117992925000037/0001179929-25-000037-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday, reflects confidence in the company's potential. The total transaction value is $3,773,402.
In the Wednesday's morning session, Molina Healthcare's shares are currently trading at $310.0, experiencing a up of 1.15%.
<h3>Discovering Molina Healthcare: A Closer Look</h3>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Molina Healthcare's Economic Impact: An Analysis</h3>
Revenue Growth: Over the 3 months period, Molina Healthcare showcased positive performance, achieving a revenue growth rate of 16.04% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Navigating Financial Profits:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 10.6%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Molina Healthcare's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 4.482143.
</li>
</ul>
Debt Management: With a high debt-to-equity ratio of 0.69, Molina Healthcare faces challenges in effectively managing its debt levels, indicating potential financial strain.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 15.01 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 0.44 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Molina Healthcare's EV/EBITDA ratio, lower than industry averages at 5.89, indicates attractively priced shares.
</li>
</ul>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions serve as a piece of the puzzle in investment decisions, rather than the entire picture.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Deciphering Transaction Codes in Insider Filings</h3>
Digging into the details of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their attention to those taking place in the open market, as outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001179929">Check Out The Full List Of Molina Healthcare's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Jeff D Barlow Of Molina Healthcare Shows Optimism, Buys $3.77M In Stock

Wells Fargo analyst Stephen Baxter upgrades Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) from Equal-Weight to Overweight and raises the price target from $295 to $372.

Upgrades

Price Target

Wells Fargo Upgrades Molina Healthcare to Overweight, Raises Price Target to $372

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Molina Healthcare, revealing an average target of $349.29, a high estimate of $376.00, and a low estimate of $325.00. Observing a downward trend, the current average is 6.71% lower than the prior average price target of $374.43. 
<img src="https://www.benzinga.com/files/images/story/2025/1741024854_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Molina Healthcare. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$376.00</td>
<td>$382.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$340.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$339.00</td>
<td>$372.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$325.00</td>
<td>$374.00</td>
</tr>
<tr>
<td>Raj Kumar</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$345.00</td>
<td>$345.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$370.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>John Stansel</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$350.00</td>
<td>$378.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Molina Healthcare. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Molina Healthcare compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Molina Healthcare's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Molina Healthcare's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MOH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Molina Healthcare analyst ratings.</a>
<h2>Get to Know Molina Healthcare Better</h2>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Unraveling the Financial Story of Molina Healthcare</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Molina Healthcare's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 16.04% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Molina Healthcare's net margin excels beyond industry benchmarks, reaching 2.39%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Molina Healthcare's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.42%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Molina Healthcare's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.6%, the company showcases efficient use of assets and strong financial health.
Debt Management: Molina Healthcare's debt-to-equity ratio is below the industry average. With a ratio of 0.69, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 7 Analyst Ratings Have To Say About Molina Healthcare

Mizuho analyst Ann Hynes maintains Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Outperform and lowers the price target from $382 to $376.

Mizuho Maintains Outperform on Molina Healthcare, Lowers Price Target to $376

Shares of major healthcare companies such as The Cigna Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) and UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) dropped Wednesday following the signing of an executive order by President Donald Trump aimed at strengthening price transparency regulations <a href="https://www.benzinga.com/insights/options/25/02/43981978/10-health-care-stocks-whale-activity-in-todays-session">in the industry.</a>
What To Know: The order, signed on Feb. 25, directs federal agencies, including the Departments of Treasury, Labor and Health and Human Services, to enforce and expand a 2019 rule that requires hospitals and insurers to publicly disclose the actual costs of medical services. This initiative seeks to eliminate price secrecy and provide consumers with clearer information on healthcare expenses according to Reuters.
The original 2019 rule required hospitals to display pricing information for up to 300 shoppable services in a consumer-friendly format and maintain a machine-readable file of negotiated rates for every service provided. Additionally, health insurance companies were mandated to disclose their negotiated rates with healthcare providers, their out-of-network payments, and the actual costs they or their pharmacy benefit managers pay for prescription drugs.
The renewed push for transparency has raised concerns among investors that stricter enforcement could impact revenue streams for hospitals and insurers. With healthcare companies required to publish actual prices rather than estimates, there is speculation that insurers may face increased pressure to negotiate lower rates with providers, potentially affecting profit margins. 
Price Action: The Cigna Group shares were down 2.27% to $306.77, Molina Healthcare shares dropped 7.95% to $281.65 and UnitedHealth Group shares declined 1.89% to $461.50 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43987636/bitcoin-tumbles-below-85000-amid-president-trumps-eu-tariff-threats">Bitcoin Tumbles Below $85,000 Amid President Trump&#8217;s EU Tariff Threats</a></li>
</ul>
Image via Shutterstock.

Healthcare Stocks Decline After Trump Signs Executive Order On Price Transparency

WIIM

Shares of healthcare stocks are trading lower after President Trump signed an executive order on healthcare price transparency.

Shares of health insurers are trading lower. Weakness in the sector may be in sympathy with UnitedHealth, which fell on reports of a DOJ investigation into Medicare billing practices.

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has outperformed the market over the past 20 years by 3.61% on an annualized basis producing an average annual return of 12.0%. Currently, Molina Healthcare has a market capitalization of $15.57 billion. 
Buying $1000 In MOH: If an investor had bought $1000 of MOH stock 20 years ago, it would be worth $9,635.36 today based on a price of $280.50 for MOH at the time of writing.
<h3>Molina Healthcare's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740156309_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today

Molina Healthcare's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) short percent of float has fallen 8.77% since its last report. The company recently reported that it has 1.04 million shares sold short, which is 2.08% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.7 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Molina Healthcare Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740073516_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Molina Healthcare has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Molina Healthcare's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Molina Healthcare's peer group average for short interest as a percentage of float is 5.08%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Is the Market Bullish or Bearish on Molina Healthcare?

Truist Securities analyst David Macdonald maintains Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Buy and lowers the price target from $370 to $340.

Truist Securities Maintains Buy on Molina Healthcare, Lowers Price Target to $340

On Tuesday, Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) posted a fourth-quarter adjusted earnings per share loss of $2.16. That&#8217;s down from 11 cents a year ago, <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">in line with the consensus</a> and including <a href="https://www.benzinga.com/government/regulations/25/01/43173248/us-health-agency-cms-to-appeal-medicare-star-ratings-recalculation-ruling" target="_blank" rel="noreferrer noopener">incremental investments in Stars</a>.
The company reported revenues of $29.19 billion, up 13.5% year-over-year from $25.73 billion, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/25/02/43621782/insurance-giant-humanas-q4-earnings-at-par-with-estimates-2025-profit-outlook-falls-below-street-view" rel="noreferrer noopener">consensus of $28.84 billion</a>.
For 2025, Humana expects its insurance segment's benefit ratio guidance of approximately 90.1-90.5%.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/43321236/rfk-jr-and-big-pharma-stocks-to-watch-as-health-secretary-hopeful-answers-pointed-questions-on-drugs-insurance-trump-exec-orders" rel="noreferrer noopener">RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders</a>
Cantor Fitzgerald expects a more cautious approach to cost trend assumptions. However, analysts Sarah James and Gabie Ingoglia acknowledge the reasoning behind expecting some moderation.
&#8220;We have incremental concerns over outlier assumptions on cost trends though find some logic in the rationale, and we believe the Street may be underestimating the earnings power in turning around the group MA book in &#8217;26 and &#8217;27, which we estimate could represent a $1-2 earnings drag to 2025,&#8221; the analysts wrote.
Humana stands out by projecting a slowdown in the 2025 cost trend to the mid-single digits compared to the high-single digits in 2024. This contrasts with UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), Elevance Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), and Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), which anticipate continued elevated trends from 2024.
Humana attributes the expected slowdown to factors that won't repeat in 2025, such as the impact of the &#8220;two-midnight&#8221; rule, though it still expects high specialty drug costs. The company also noted stable cost trends from Q3 to Q4 2024, except for seasonal increases in supplemental benefits that drive year-end utilization.
Management plans to aggressively cut costs and AEP results confirm the company&#8217;s pricing strategy is working, analysts say. However, the company lost about 30,000 D-SNP members due to redetermination.
Another positive is that the PDP pricing strategy isn't facing issues.
Price Action: Humana stock is up 0.80% at $259.40 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43662901/why-is-nano-cap-cancer-focused-xilio-therapeutics-stock-trading-over-100-on-wednesday" target="_blank" rel="noreferrer noopener">Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday?</a></li>
</ul>
Image: Shutterstock

Humana 2025 Outlook Shows Cautious Optimism Despite Industry Pressures

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has outperformed the market over the past 10 years by 5.8% on an annualized basis producing an average annual return of 16.94%. Currently, Molina Healthcare has a market capitalization of $16.24 billion. 
Buying $100 In MOH: If an investor had bought $100 of MOH stock 10 years ago, it would be worth $486.42 today based on a price of $283.97 for MOH at the time of writing.
<h3>Molina Healthcare's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738967409_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Molina Healthcare Stock In The Last 10 Years

Barclays analyst Andrew Mok maintains Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Equal-Weight and lowers the price target from $372 to $339.

Barclays Maintains Equal-Weight on Molina Healthcare, Lowers Price Target to $339

UBS analyst Kevin Caliendo maintains Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Neutral and lowers the price target from $374 to $325.

UBS Maintains Neutral on Molina Healthcare, Lowers Price Target to $325

Press Releases

Molina Healthcare Wins Michigan Contract to Provide a New Dual Eligible Benefit Program

Molina Healthcare Reports Third Quarter 2024 Financial Results

Molina Healthcare Announces Proposed Offering of $500 Million of Senior Notes Due 2033

Molina Healthcare Announces Pricing of $750 Million of 6.250% Senior Notes Due 2033

Molina Healthcare Announces Closing of Offering of $750 Million of 6.250% Senior Notes Due 2033

Molina Healthcare Awarded Contracts to Serve Dual Eligible Populations in Michigan and Idaho

Molina Healthcare Announces Fourth Quarter and Year-End 2024 Earnings Release and Conference Call Dates

Molina Healthcare Announces the Closing of its Acquisition of ConnectiCare

Molina Healthcare Reports Fourth Quarter and Year-End 2024 Financial Results

Molina Healthcare Announces First Quarter 2025 Earnings Release and Conference Call Dates

Alignment Healthcare, Inc. - Common Stock

Alignment Healthcare

Clover Health Investments, Corp. - Class A Common stock

Clover Health Investments

Centene

Elevance Health

HealthEquity

Humana

NeueHealth

Progyny

UnitedHealth Group Incorporated Common Stock (DE)

UnitedHealth Group

Wells Fargo

Mizuho

Truist Securities

Barclays

시그나 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), 몰리나 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), 유나이티드헬스 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) 같은 <a href="https://www.benzinga.com/insights/options/25/02/43981978/10-health-care-stocks-whale-activity-in-todays-session" target="_blank" rel="noopener">주요 의료 서비스 회사들의 주가</a>는 도널드 트럼프 대통령이 헬스케어 산업의 가격 투명성 규제를 강화하기 위한 행정명령에 서명한 이후 수요일(26일) 하락했다.
알아둘 내용: 2월 25일에 서명된 이 행정명령은 재무부, 노동부, 보건복지부를 포함한 연방 기관에 병원과 보험사가 의료 서비스의 실제 비용을 공개하도록 요구하는 2019년 규칙을 시행하고 확대할 것을 지시한다. 이 계획은 가격 기밀을 없애고 소비자에게 의료 서비스 비용에 대한 명확한 정보를 제공하기 위한 것이라고 로이터 통신은 전했다.
2019년 초반의 규칙은 병원이 소비자 친화적인 형식으로 최대 300가지의 구매 가능한 서비스에 대한 가격 정보를 표시하고, 제공되는 모든 서비스에 대한 협상된 요금의 기계 판독 가능 파일을 유지하도록 요구했다. 또한, 건강보험 회사는 의료 서비스 제공자와의 협상된 요금, 네트워크 외부 지불, 그리고 처방약에 대해 본인 또는 약국 혜택 관리자가 지불하는 실제 비용을 공개하도록 의무화했다.
투명성에 대한 새로운 요구는 투자자들 사이에서 더 엄격한 집행이 병원과 보험사의 매출에 영향을 미칠 수 있다는 우려를 불러일으켰다. 헬스케어 서비스 회사들이 예상 가격이 아닌 실제 가격을 공개해야 하는 상황에서, 보험사가 헬스케어 서비스 제공자와 더 낮은 요율을 협상해야 한다는 압박을 받을 수 있다는 추측이 제기되고 있으며, 이는 잠재적으로 수익 마진에 영향을 미칠 수 있다.
주가 움직임: <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2" target="_blank" rel="noopener">Benzinga Pro에</a> 따르면, 시그나 그룹의 주가는 2.73% 하락한 305.34달러, 몰리나 헬스케어는 6.95% 하락한 284.71달러, 유나이티드헬스 그룹은 1.44% 하락한 463.59달러로 마감했다.
이미지 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

미국의 의료 보험 회사 휴매나(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>)의 주식은 수요일 소폭 상승 마감했다. 화요일 이 회사는 4분기 조정 주당순이익이 2.16달러 손실이라고 발표했다. 이는 전년 대비 11센트 감소한 수치로, <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">컨센서스와 일치</a>하며 <a href="https://www.benzinga.com/government/regulations/25/01/43173248/us-health-agency-cms-to-appeal-medicare-star-ratings-recalculation-ruling" target="_blank" rel="noreferrer noopener">별 등급제에 대한 추가 투자</a>를 포함한 것이다.
이 회사는 매출이 291억 9천만 달러로, 전년 대비 257억 3천만 달러에서 13.5% 증가하여 <a href="https://www.benzinga.com/25/02/43621782/insurance-giant-humanas-q4-earnings-at-par-with-estimates-2025-profit-outlook-falls-below-street-view" target="_blank" rel="noreferrer noopener">컨센서스 288억 4천만 달러</a>를 초과했다고 보고했다.
휴매나는 2025년 보험 부문의 손익 비율 가이던스를 약 90.1-90.5%로 예상하고 있다.
또한 읽어보기: <a href="https://www.benzinga.com/general/health-care/25/01/43321236/rfk-jr-and-big-pharma-stocks-to-watch-as-health-secretary-hopeful-answers-pointed-questions-on-drugs-insurance-trump-exec-orders" target="_blank" rel="noreferrer noopener">RFK Jr.와 대제약사: 보건부 장관 후보가 약물, 보험, 트럼프 행정명령에 대한 날카로운 질문에 답변</a>
캔터 피츠제럴드는 비용 추세 가정에 대해 보다 신중한 접근을 예상한다. 그러나 애널리스트인 사라 제임스(Sarah James)와 가비 잉골리아(Gabie Ingoglia)는 일부 조정이 필요하다는 논리에는 동의한다.
&#8220;우리는 비용 추세에 대한 이례적인 가정에 대해 우려를 가지고 있으나, 그 논리에는 일정 부분 타당성이 있다고 생각한다. 또한, 시장이 2026년과 2027년에 그룹 MA 상품을 회복하는 데 있어 이익 잠재력을 과소평가하고 있을 수 있다고 믿고 있다. 이는 2025년에는 $1-2의 이익 감소 요인으로 작용할 수 있다&#8221;라고 이 애널리스트들이 언급했다.
휴매나는 2025년 비용 추세가 중간 단일 자릿수로 둔화될 것으로 예상하는 점에서 두드러진다. 이는 2024년의 높은 단일 자릿수와 대조적이다. 반면, 유나이티드헬스 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), 엘레반스 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) 및 몰리나 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>)는 2024년부터 계속해서 높은 추세가 유지될 것으로 예상하고 있다.
휴매나는 2025년에는 반복되지 않을 요인, 즉 &#8220;두 자정&#8221; 규정의 영향을 기대하며, 여전히 높은 전문 약품 비용을 예상하고 있다. 이 회사는 또한 2024년 3분기에서 4분기까지 안정적인 비용 추세가 유지되지만, 연말 이용률을 증가시키는 보충 혜택의 계절적 증가가 있다고 언급했다.
경영진은 비용을 공격적으로 절감할 계획이며, AEP 결과는 회사의 가격 책정 전략이 효과를 보고 있음을 확인한다. 그러나 이 회사는 재심사로 인해 약 30,000명의 D-SNP 회원을 잃었다.
또 다른 긍정적인 점은 PDP 가격 책정 전략이 문제에 직면하지 않고 있다는 것이다.
가격 동향: 휴매나의 주식은 수요일 0.76% 상승 260.03달러에 마감되었다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43662901/why-is-nano-cap-cancer-focused-xilio-therapeutics-stock-trading-over-100-on-wednesday" target="_blank" rel="noreferrer noopener">왜 나노-캡 암 중심의 자일리오 테라퓨틱스 주식이 수요일에 100% 이상 거래되고 있나요?</a></li>
</ul>
이미지 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

2008년 금융 위기를 예측한 것으로 유명한 헤지펀드 매니저인 마이클 버리(Michael Burry)는 2008년 금융 위기를 예측한 것으로 유명한 헤지펀드 매니저로, 최근 중국 기술 기업에 대한 노출을 크게 늘렸으며 동시에 잠재적 하방 위험에 대한 보호 조치를 시행했다고 <a href="https://www.benzinga.com/markets/asia/24/11/42000692/david-teppers-appaloosa-trims-alibaba-stake-by-476-in-q3-2024-doubles-down-on-pdd-holdings-and-jd.com">규제 공시</a>에서 밝혔다.
무슨 일이 있었나: 버리의 사이언 에셋 매니지먼트(Scion Asset Management)는 3분기 동안 포트폴리오에 몇 가지 주목할 만한 조정을 했으며, 이제 중국 기업들이 가장 큰 비중을 차지하고 있다. 이 회사는 알리바바 그룹 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>)의 지분을 29% 늘려 9월 말 기준으로 2,100만 달러 이상의 가치로 펀드의 최대 보유 종목으로 만들었다.
비슷한 방식으로, 사이언은 JD닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>)의 지분을 두 배로 늘려 약 2,000만 달러로 펀드의 두 번째 대형 보유 종목으로 만들었다. 또한, 중국 검색 거대 기업인 바이두(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>)에 대한 투자도 67% 증가시켜 1,320만 달러에 달했다.
하지만, 버리는 이러한 보유 종목에 대한 풋 옵션을 동시에 설정하여 조심스러운 전략을 취한 것으로 보인다. 풋 옵션은 기초 증권의 가치가 하락할 때 가치가 상승하는 경향이 있어, 시장 변동성에 대한 보호 전략으로 해석된다.
이러한 움직임은 베이징이 세계에서 두 번째로 큰 경제 성장률을 회복하기 위한 최근 경제 부양책 발표와 동시에 이루어졌다. 중국 주식은 이러한 신호가 나타난 후 9월에 처음으로 반등했지만, 투자자들이 더 구체적인 재정 조치를 기다리면서 상승폭은 완화되었다.
중국 기술 중심 외에도, 버리는 시프트4 페이먼츠(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>), 아메리칸 코스탈 인슈어런스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>) 및 몰리나 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>)와 같은 여러 미국 기업에 대한 포지션도 늘렸다.
중요한 이유는: 버리의 <a href="https://www.benzinga.com/markets/equities/24/10/41248334/big-short-investor-michael-burrys-china-bet-pays-off-as-top-picks-surge-nearly-60-in-2-months">상위 세 개의 중국 보유 종목</a>은 두 달 동안 평균적으로 약 60%의 수익률을 기록했다고 한다.
버리의 움직임은 그의 트랙레코드를 고려할 때 시장 참여자들에 의해 면밀히 주시되고 있다. 그는 2008년 세계 금융 위기 이전에 모기지 담보 증권에 대한 선견지명이 있는 베팅으로 널리 알려졌으며, 이 이야기는 나중에 마이클 루이스의 베스트셀러 &#8220;빅 쇼트&#8221;와 그 후속 아카데미상 수상 영화로 기록되었다.
이러한 포지션은 9월 30일 기준으로 미 증권거래위원회(SEC) 규정에 따라 1억 달러 이상의 자산을 관리하는 펀드에 요구되는 보유 종목을 반영한다. 45일의 보고 지연과 버리의 적극적인 거래 스타일을 고려할 때, 현재 포지션은 이미 변경되었을 수 있다.
이러한 전개는 다른 <a href="https://www.benzinga.com/markets/asia/24/11/42000692/david-teppers-appaloosa-trims-alibaba-stake-by-476-in-q3-2024-doubles-down-on-pdd-holdings-and-jd.com">저명한 투자자들이 중국 보유 종목을 조정하는 것과</a> 동시에 일어났다. 억만장자 투자자 데이비드 테퍼의 아팔루사 매니지먼트는 최근 알리바바 지분을 5% 줄였지만, 여전히 펀드의 최대 보유 종목으로 67억 달러 포트폴리오의 15.75%를 차지하고 있다.

다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/content/41999311/jim-cramer-says-these-10-frothy-stocks-are-up-over-200-ytd-including-rocket-lab-palantir-and-carvana">짐 크레이머가 올 해 200% 이상 상승한 &#8216;거품 주식&#8217; 10개를 언급하다: 로켓랩, 팔란티어, 카바나 포함</a></li>
</ul>
이미지 출처: Shutterstock
면책 조항:이 콘텐츠는 AI 도구의 도움으로 부분적으로 제작되었으며, 벤징가 편집자에 의해 검토 및 게시되었습니다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

'빅 쇼트' 투자자 마이클 버리, 중국 기술주에 베팅 확대하면서 보호 헤지 추가

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)의 주식은 실적 <a href="https://www.benzinga.com//node/41537560" target="_blank" rel="noreferrer noopener">호조와 전반적인 시장 강세</a>로 인해 21.97% 상승했다.
2. 리 오토(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>)의 주식은 중국 인민은행이 <a href="https://www.benzinga.com//node/41547149" target="_blank" rel="noreferrer noopener">7,000억 위안</a>($9,836억 달러)를 은행 시스템에 주입하고 금리를 2.0%로 유지한 후 14.02% 상승했다.
3. 몰리나 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/41500855" target="_blank" rel="noreferrer noopener">3분기 실적을 발표</a>한 후 12.36% 급등했다.
4. 태피스트리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>)의 주식은 자사의 카프리 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>) 인수 제안이 <a href="https://www.benzinga.com//node/41550527" target="_blank" rel="noreferrer noopener">법원에 의해 차단되었다는 보도</a> 이후 11.83% 상승했다. 이 회사는 이 결정에 대해 항소할 계획이라고 밝혔다.
5. 앱러빈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>)의 주식은 여러 애널리스트들이 주가 전망을 <a href="https://www.benzinga.com/quote/APP/analyst-ratings" target="_blank" rel="noreferrer noopener">상향 조정한</a> 후 11.30% 상승했다.
6. 부즈 앨런 해밀턴 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>)의 주식은 2분기 재무 실적이 예상보다 좋게 나타나고 <a href="https://www.benzinga.com//node/41543105" target="_blank" rel="noreferrer noopener">2025 회계연도 가이던스가 강하게 나타난</a> 후 10.99% 상승했다.
7. 디지털 리얼티 트러스트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>)의 주식은 3분기 FFO 실적이 예상보다 좋고 2024 회계연도 FFO 가이던스를 상향 조정한 후 9.45% 상승했다. 여러 애널리스트들이 주가 전망을 <a href="https://www.benzinga.com/quote/DLR/analyst-ratings" target="_blank" rel="noreferrer noopener">상향 조정</a>했다.
8. 그랩 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>)의 주식은 다이와 캐피털(Daiwa Capital)이 주식을 아웃퍼폼 등급으로 <a href="https://www.benzinga.com/quote/GRAB/analyst-ratings" target="_blank" rel="noreferrer noopener">커버리지 개시하고 $4.60의 목표 주가를 제시</a>한 후 9.12% 상승했다.
9. 마이크로스트레티지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)의 주식은 비트코인 가격 상승으로 <a href="https://www.benzinga.com//node/41544385" target="_blank" rel="noreferrer noopener">8.56% 상승</a>했다.
10. 필립 모리스 인터내셔널(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>)의 주식은 회사가 3분기 실적이 예상보다 좋게 나타나고 여러 애널리스트들이 목표 주가를 <a href="https://www.benzinga.com//node/41499153" target="_blank" rel="noreferrer noopener">상향 조정한</a> 후 8.03% 상승했다.
Photo via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

CPRI

GRAB

MSTR

TSLA

테슬라와 리 오토는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (10월 21일-10월 25일)

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 니오(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>)의 주식이 지난주 16.35% 하락했다. 이는 미국에 상장된 중국 주식들이 <a href="https://www.benzinga.com//node/41385461" target="_blank" rel="noreferrer noopener">중국의 9월 수출이 예상치를 밑돌면서</a> 하락한 후 발생한 일이다. 중국 경기 부양책에 대한 불확실성도 최근 주식에 악영향을 미쳤다.
2. KLA 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>)의 주식이 지난주 15.58% 하락했다. 이는 ASML의 부진한 전망 발표 이후 지속적인 약세로 인한 것으로 보인다.
3. 센텐 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>)의 주식이 14.38% 하락했다. 이 회사는 <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">10월 25일 3분기 실적을 발표</a>할 예정이다.
4. 엘레반스 헬스(Elevance Health)의 주식이 14.17% 하락했다. 이는 분석가들이 <a href="https://www.benzinga.com//node/41405601" target="_blank" rel="noreferrer noopener">3분기 실적 발표 후 전망을 하향 조정한</a> 데 따른 것이다.
5. ASML 홀딩 N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>)의 주식이 13.97% 하락했다. 회사가 실적 발표를 하루 일찍 실수로 공개하고 <a href="https://www.benzinga.com//node/41358875" target="_blank" rel="noreferrer noopener">2025년 매출 전망을 하향 조정한</a> 후 발생한 일이다.
6. PDD 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>)의 주식이 13.91% 하락했다. 이는 미국에 상장된 중국 주식들이 <a href="https://www.benzinga.com//node/41316058" target="_blank" rel="noreferrer noopener">중국의 9월 수출이 예상치를 밑돌면서</a> 하락한 것과 함께 발생한 일이다. 중국 경기 부양책에 대한 불확실성도 최근 주식에 악영향을 미쳤다.
7. 몰리나 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>)의 주식이 12.24% 하락했다. 이는 엘레반스 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>)와 동반 하락한 것으로 보인다. 엘레반스 헬스는 3분기 실적 부진과 2024년 전망을 낮춰 발표했다.
8. 램 리서치(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>)의 주식이 12.12% 하락했다. 이는 ASML의 부진한 전망 발표 이후 지속적인 약세로 인한 것으로 보인다.
9. 이리 인뎀니티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIE#NASDAQ">ERIE</a>)의 주식이 지난주 9.92% 하락했다. 이는 스프루스 포인트 매니지먼트(Spruce Point Management)가 주식에 대한 <a href="https://www.sprucepointcap.com/research/erie-indemnity-company" target="_blank" rel="noreferrer noopener">공매도 보고서를 발표</a>한 후 발생한 일이다. 이 회사는 카테고리 5 허리케인 밀턴으로 압박을 받았다.
10. CVS 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)의 주식이 지난 주 9.44% 하락했다. 이 회사가 <a href="https://www.benzinga.com//node/41399396" target="_blank" rel="noreferrer noopener">3분기 전망을 하향 조정</a>한 후 발생한 일이다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%BD%94%EC%9D%B8%EB%B2%A0%EC%9D%B4%EC%8A%A4%EC%99%80-%EC%9C%A0%EB%82%98%EC%9D%B4%ED%8B%B0%EB%93%9C-%ED%95%AD%EA%B3%B5%EC%9D%80-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC/" target="_blank" rel="noopener">코인베이스, 유나이티드 항공 및 소파이 테크가 지난 주 가장 큰 대형주 상승 종목 중 하나 (10월 14-18일): 다른 종목들은 여러분의 포트폴리오에 포함되어 있나요?</a></li>
</ul>
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

ASML

ERIE

KLAC

LRCX

니오, ASML 및 CVS 헬스는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (10월 14일-18일)

2008년 금융 위기 이전 주택 시장에 대한 선견지명 있는 투자로 유명한 유명 투자자 마이클 버리(Michael Burry)는 2024년 2분기에 자신의 헤지 펀드 포트폴리오에 큰 변화를 주었다.
어떤 일이 (What Happened): 사라토가에 본사를 두고 버리가 운영하는 사이언 에셋 매니지먼트(Scion Asset Management)는 수요일 미국 증권거래위원회(SEC)에 최신 13F 보고서를 제출하여 투자 전략의 주목할만한 변화를 밝혔다.
주요 포인트들은 다음과 같다:
<ol>
<li>알리바바 그룹 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>)가 1위 자리를 차지함: 중국의 전자상거래 대기업인 알리바바는 155,000주로 구성된 약 1,116만 달러의 가치를 지닌 사이언의 최대 보유 기업이 되었다.</li>
<li>기술 초점: 이 포트폴리오는 중국 기술 기업들에 대한 지속적인 관심을 보여준다. 이에는 75,000주로 약 649만 달러의 가치를 형성하는 바이두(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>)와 25만 주로 646만 달러의 가치를 형성하는 징동닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>)의 큰 비중이 포함되어 있다.</li>
<li>헬스케어 및 핀테크: 몰리나 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>)와 시프트4 페이먼츠(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>)는 각각 729만 달러와 734만 달러 상당의 상당한 투자를 보여준다.</li>
<li>부동산 노출: 허드슨 퍼시픽 프로퍼티즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPP#NYSE">HPP</a>)는 550만 달러 상당의 주식 110만 주를 보유한 중요한 부동산 회사로 두각을 나타낸다.</li>
<li>바이오테크 신생기업: 임상 단계의 바이오제약 회사인 바이오아틀라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>)는 포트폴리오에서 작지만 주목할만한 위치를 나타낸다.</li>
</ol>
기타 주목할만한 보유 자산으로는 더 리얼리얼(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REAL#NASDAQ">REAL</a>), 올라플렉스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLPX#NASDAQ">OLPX</a>), 그리고 아메리칸 코스탈 인슈어런스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>)가 있다.
중요성 (Why It Matters): 이 최신 서류는 버리의 현재 시장 전망에 대한 통찰력을 제공하며 중국 기술 기업, 미국 의료, 핀테크 및 엄선된 부동산 기회에 대한 상당한 투자를 통한 다양한 접근 방식을 제안한다.
지난 5월 버리는 <a href="https://www.benzinga.com/markets/asia/24/05/38878116/big-short-investor-michael-burry-bets-heavy-on-gold-renewable-energy-stocks-exits-amazon-alphabet">금 및 신재생 에너지</a>에 대한 막대한 투자로 헤드라인을 장식했으며 아마존닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) 및 알파벳(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)에서 포지션을 청산했다. 이 전환점은 실물 상품과 지속 가능한 에너지원에 초점을 맞추었음을 나타낸다.
관련해서, <a href="https://www.benzinga.com/general/entertainment/24/07/39695004/elon-musk-warren-buffett-nancy-pelosi-jensen-huang-michael-saylor-who-you-sitting-by-on-a-p">최근의 설문 조사</a>에서는 투자자들이 일론 머스크, 워런 버핏, Burry 자신과 같은 최고 인물들로부터 조언을 구하는 방법을 강조하여 투자 커뮤니티에서 그의 영향력을 강조한다.
Michael Burry illustration by Gonzalo Lanzilotta for
면책 조항: 본 콘텐츠는 인공지능 도구의 도움을 받아 제작되었으며, Benzinga 편집자들에 의해 검토되고 게시되었습니다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Asia

AMZN

BCAB

GOOG

GOOGL

OLPX

REAL

'빅쇼트' 명성의 마이클 버리, 중국에 큰 투자하고 알리바바를 최대 보유 주식으로 공개

이들 11개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>QXO(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>)의 주가는 <a href="https://www.benzinga.com//node/39880836" target="_blank" rel="noreferrer noopener">사모 금융 유치</a>를 발표한 이후 33.37% 상승했다.</li>
<li>아반토(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>)의 주식은 S&amp;P MidCap 400에 편입된다는 발표 이후 지난 주에 21.62% 상승했다. 또한 예상보다 나은 2분기 실적을 발표했다.</li>
<li>유니버셜 헬스 서비스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>)는 회사가 예상보다 나은 2분기 실적을 발표하고 <a href="https://www.benzinga.com//node/39942622" target="_blank" rel="noreferrer noopener">2024 회계연도 지침을</a> 상향 조정한 후 주가가 17.73% 상승했다.</li>
<li>맨하탄 어소시에이츠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>)의 주가는 예상보다 나은 2분기 재무 결과를 보고한 후 17.02% 상승했다. 몇몇 분석가들은 주식에 대한 가격 <a href="https://www.benzinga.com/quote/MANH/analyst-ratings" target="_blank" rel="noreferrer noopener">예측</a>을 높였다.</li>
<li>몰리나 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>)의 주가는 <a href="https://www.benzinga.com//node/39942485" target="_blank" rel="noreferrer noopener">예상보다 좋은 2분기 실적</a>에 힘입어 15.53% 상승했다.</li>
<li>퍼스트 시티즌스 뱅크셰어스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>)의 주가는 회사의 분기 실적이 예상보다 높았음을 보고한 후 15.15% 상승했다.</li>
<li>테넷 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>)는 예상보다 나은 2분기 재무 결과를 보고한 후 주가가 13.02% 상승했으며, 회사는 FY24 지침을 추정치보다 높이고 3분기 지침을 추정치보다 높게 발표했다. 또한 회사는 <a href="https://www.benzinga.com//node/39934114" target="_blank" rel="noreferrer noopener">15억 달러 규모의</a> 자사주 매입을 승인했다고 발표했다.</li>
<li>CBRE 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>)은 회사가 2024년 목표를 상향 조정한 후 지난 주 주가가 12.99% 상승했다. 몇몇 분석가들은 주식에 대한 가격 <a href="https://www.benzinga.com/quote/MANH/analyst-ratings" target="_blank" rel="noreferrer noopener">예측</a>을 높였다.</li>
<li>써모 피셔 사이언티픽(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>)의 주가는 지난주 12.63% 상승했다. 이 회사는 연간 전망을 <a href="https://www.benzinga.com//node/39930516" target="_blank" rel="noreferrer noopener">상향 조정</a>했다.</li>
<li>다나허(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>)의 주가는 회사가 예상보다 나은 2분기 실적을 보고한 후 11.30% 상승하여 더 높게 거래되고 있다.</li>
<li>록히드 마틴(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>)의 주가는 긍정적인 애널리스트 <a href="https://www.benzinga.com//node/39941283" target="_blank" rel="noreferrer noopener">평가와 강한 2분기 실적</a>에 힘입어 10.72% 상승했다.</li>
</ol>
다음 기사:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ed%8f%ac%eb%93%9c-%ec%8a%a4%ed%85%94%eb%9e%80%ed%8b%b0%ec%8a%a4-%eb%b0%8f-%eb%8d%b8%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-12/" target="_blank" rel="noopener">포드, 스텔란티스 및 델은 지난주 최악의 성과를 보인 12개 대형주 중 일부 (7월 21일~7월 27일)</a></li>
</ul>
썸네일 제공: 셔터스톡
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Molina Healthcare

뉴스

에 대한 최신 뉴스 Molina Healthcare (NYSE:MOH) 주식

목요일, 2월 27, 2025

수요일, 2월 12, 2025

금요일, 11월 15, 2024

토요일, 10월 26, 2024

일요일, 10월 20, 2024

목요일, 8월 15, 2024

일요일, 7월 28, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌